315 related articles for article (PubMed ID: 25271285)
21. Lead optimization of 2-hydroxymethyl imidazoles as non-hydroxamate LpxC inhibitors: Discovery of TP0586532.
Ushiyama F; Takashima H; Matsuda Y; Ogata Y; Sasamoto N; Kurimoto-Tsuruta R; Ueki K; Tanaka-Yamamoto N; Endo M; Mima M; Fujita K; Takata I; Tsuji S; Yamashita H; Okumura H; Otake K; Sugiyama H
Bioorg Med Chem; 2021 Jan; 30():115964. PubMed ID: 33385955
[TBL] [Abstract][Full Text] [Related]
22. TP0586532, a non-hydroxamate LpxC inhibitor, has in vitro and in vivo antibacterial activities against Enterobacteriaceae.
Fujita K; Takata I; Yoshida I; Okumura H; Otake K; Takashima H; Sugiyama H
J Antibiot (Tokyo); 2022 Feb; 75(2):98-107. PubMed ID: 34837061
[TBL] [Abstract][Full Text] [Related]
23. Discovery of Novel Inhibitors of LpxC Displaying Potent in Vitro Activity against Gram-Negative Bacteria.
Surivet JP; Panchaud P; Specklin JL; Diethelm S; Blumstein AC; Gauvin JC; Jacob L; Masse F; Mathieu G; Mirre A; Schmitt C; Lange R; Tidten-Luksch N; Gnerre C; Seeland S; Herrmann C; Seiler P; Enderlin-Paput M; Mac Sweeney A; Wicki M; Hubschwerlen C; Ritz D; Rueedi G
J Med Chem; 2020 Jan; 63(1):66-87. PubMed ID: 31804826
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and structure-activity relationship evaluation of novel LpxC inhibitors as Gram-negative antibacterial agents.
Ding S; Dai RY; Wang WK; Cao Q; Lan LF; Zhou XL; Yang YS
Bioorg Med Chem Lett; 2018 Jan; 28(2):94-102. PubMed ID: 29233653
[TBL] [Abstract][Full Text] [Related]
25. Small molecule LpxC inhibitors against gram-negative bacteria: Advances and future perspectives.
Niu Z; Lei P; Wang Y; Wang J; Yang J; Zhang J
Eur J Med Chem; 2023 May; 253():115326. PubMed ID: 37023679
[TBL] [Abstract][Full Text] [Related]
26. Lipid a biosynthesis of multidrug-resistant pathogens - a novel drug target.
Lee CR; Lee JH; Jeong BC; Lee SH
Curr Pharm Des; 2013; 19(36):6534-50. PubMed ID: 23829374
[TBL] [Abstract][Full Text] [Related]
27. Mechanism and inhibition of LpxC: an essential zinc-dependent deacetylase of bacterial lipid A synthesis.
Barb AW; Zhou P
Curr Pharm Biotechnol; 2008 Feb; 9(1):9-15. PubMed ID: 18289052
[TBL] [Abstract][Full Text] [Related]
28. N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay.
Furuya T; Shapiro AB; Comita-Prevoir J; Kuenstner EJ; Zhang J; Ribe SD; Chen A; Hines D; Moussa SH; Carter NM; Sylvester MA; Romero JAC; Vega CV; Sacco MD; Chen Y; O'Donnell JP; Durand-Reville TF; Miller AA; Tommasi RA
Bioorg Med Chem; 2020 Dec; 28(24):115826. PubMed ID: 33160146
[TBL] [Abstract][Full Text] [Related]
29. Fragment-Based Discovery of Novel Non-Hydroxamate LpxC Inhibitors with Antibacterial Activity.
Yamada Y; Takashima H; Walmsley DL; Ushiyama F; Matsuda Y; Kanazawa H; Yamaguchi-Sasaki T; Tanaka-Yamamoto N; Yamagishi J; Kurimoto-Tsuruta R; Ogata Y; Ohtake N; Angove H; Baker L; Harris R; Macias A; Robertson A; Surgenor A; Watanabe H; Nakano K; Mima M; Iwamoto K; Okada A; Takata I; Hitaka K; Tanaka A; Fujita K; Sugiyama H; Hubbard RE
J Med Chem; 2020 Dec; 63(23):14805-14820. PubMed ID: 33210531
[TBL] [Abstract][Full Text] [Related]
30. Fluorescence-based methods to assay inhibitors of lipopolysaccharide synthesis.
Hernick M
Methods Mol Biol; 2011; 739():123-33. PubMed ID: 21567323
[TBL] [Abstract][Full Text] [Related]
31. Preclinical safety and efficacy characterization of an LpxC inhibitor against Gram-negative pathogens.
Zhao J; Cochrane CS; Najeeb J; Gooden D; Sciandra C; Fan P; Lemaitre N; Newns K; Nicholas RA; Guan Z; Thaden JT; Fowler VG; Spasojevic I; Sebbane F; Toone EJ; Duncan C; Gammans R; Zhou P
Sci Transl Med; 2023 Aug; 15(708):eadf5668. PubMed ID: 37556556
[TBL] [Abstract][Full Text] [Related]
32. A method to assay inhibitors of lipopolysaccharide synthesis.
Hernick M; Fierke CA
Methods Mol Med; 2008; 142():143-54. PubMed ID: 18437312
[TBL] [Abstract][Full Text] [Related]
33. Synthesis, structure, and antibiotic activity of aryl-substituted LpxC inhibitors.
Liang X; Lee CJ; Zhao J; Toone EJ; Zhou P
J Med Chem; 2013 Sep; 56(17):6954-6966. PubMed ID: 23914798
[TBL] [Abstract][Full Text] [Related]
34. Species-specific and inhibitor-dependent conformations of LpxC: implications for antibiotic design.
Lee CJ; Liang X; Chen X; Zeng D; Joo SH; Chung HS; Barb AW; Swanson SM; Nicholas RA; Li Y; Toone EJ; Raetz CR; Zhou P
Chem Biol; 2011 Jan; 18(1):38-47. PubMed ID: 21167751
[TBL] [Abstract][Full Text] [Related]
35. LpxC inhibitors: a patent review (2010-2016).
Kalinin DV; Holl R
Expert Opin Ther Pat; 2017 Nov; 27(11):1227-1250. PubMed ID: 28742403
[TBL] [Abstract][Full Text] [Related]
36. Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
Piizzi G; Parker DT; Peng Y; Dobler M; Patnaik A; Wattanasin S; Liu E; Lenoir F; Nunez J; Kerrigan J; McKenney D; Osborne C; Yu D; Lanieri L; Bojkovic J; Dzink-Fox J; Lilly MD; Sprague ER; Lu Y; Wang H; Ranjitkar S; Xie L; Wang B; Glick M; Hamann LG; Tommasi R; Yang X; Dean CR
J Med Chem; 2017 Jun; 60(12):5002-5014. PubMed ID: 28549219
[TBL] [Abstract][Full Text] [Related]
37. High-throughput catch-and-release synthesis of oxazoline hydroxamates. Structure-activity relationships in novel inhibitors of Escherichia coli LpxC: in vitro enzyme inhibition and antibacterial properties.
Pirrung MC; Tumey LN; McClerren AL; Raetz CR
J Am Chem Soc; 2003 Feb; 125(6):1575-86. PubMed ID: 12568618
[TBL] [Abstract][Full Text] [Related]
38. TP0586532, a non-hydroxamate LpxC inhibitor, reduces LPS release and IL-6 production both in vitro and in vivo.
Fujita K; Takata I; Yoshida I; Takashima H; Sugiyama H
J Antibiot (Tokyo); 2022 Mar; 75(3):136-145. PubMed ID: 34987187
[TBL] [Abstract][Full Text] [Related]
39. Mutants resistant to LpxC inhibitors by rebalancing cellular homeostasis.
Zeng D; Zhao J; Chung HS; Guan Z; Raetz CR; Zhou P
J Biol Chem; 2013 Feb; 288(8):5475-86. PubMed ID: 23316051
[TBL] [Abstract][Full Text] [Related]
40. Para-(benzoyl)-phenylalanine as a potential inhibitor against LpxC of Leptospira spp.: homology modeling, docking, and molecular dynamics study.
Pradhan D; Priyadarshini V; Munikumar M; Swargam S; Umamaheswari A; Bitla A
J Biomol Struct Dyn; 2014; 32(2):171-85. PubMed ID: 23383626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
